Posting reference material for the Covid19 PCR and RDT tess developed by Access Bio (for which AT1 Galileo devices will be used)
Bl**mberg interview: https://www.bloomberg.com/news/videos/2020-08-12/intrivo-diagnostics-gets-fda-approval-for-covid-tests-video
Interview is with Reeve Benaron, chairman of Intrivio Diagnostics, distributer for Access Bio's PCR and RDT tests in North America
These tests are branded: CareStart COVID-19 IgM/IgG (Rapid Diagnostic Test for Detection of SARS-CoV-2 IgM/IgG Ab)...this is NOT the product using AT1 device yet...but its highly relevant.Reeve talks about:
- the accuracy of these antibody tests (both PCR and lateral flow developed by Access Bio)
- distribution/usage potential at CVS, Walgreens, Walmart etc and also for future at-home test opportunities
- future tests to differentiate influenza vs Covid19 (similar symptoms, common mis-diagnosis today)
The 'test strip' that is going to be in the Access Bio + AT1 device is this same technology. if anyone is interested in the 'instructions for usage', for how the device works:
https://intrivo.com/wp-content/uploads/2020/07/5-EUA201309-Access-Bio-IFU-Serology-07-24-2020.pdfThis is relevant to AT1 because the current CareStart
rapid test version does not have AT1 developed all-in-one integrated functions, which makes it riskier and more cumbersome for sample and testing steps. It uses
'...a separate lancet to generate a blood sample and a separate manual pipette to collect and deliver blood to the test strip'.
Here is an article referenced via AT1 website news links which also puts all this together:
https://www.biospace.com/article/releases/atomo-diagnostics-and-access-bio-partner-to-expand-access-to-covid-19-blood-based-rapid-testing-in-north-america/
Remains to be seen if these CareStart tests (the rapid test version) will utilise AT1 devices only in future (with Atomo name on labelling) or it will be a completely different product in the range (maybe with slightly higher price differentiating the with/without integrated function?)..
